Experimental evidence indicates that reducing TRAF1 expression can exacerbate the proliferation of renal cell carcinoma cells, diminish treatment-induced apoptosis, and increase resistance to Sunitinib, a key therapeutic agent [28, 29]. The gene discussed is TRAF1; the disease is hereditary clear cell renal cell carcinoma.